Evidence map›Paper›PMID 39457136›Full record

ArticleChildren (Basel, Switzerland)2024

Effect of an In-Home Palivizumab Administration Program for Children with Medical Complexity.

Hina Emanuel, Aravind Yadav, Julie C Eapan, Maria Caldas-Vasquez, Tomika S Harris, Katrina McBeth, Fatima Boricha, Janice John, Ivan G Magana Ceballos, Giuseppe N Colasurdo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Children (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hina EmanuelDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.ORCID 0000-0002-9793-8681
Aravind YadavDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Julie C EapanDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Maria Caldas-VasquezDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Tomika S HarrisDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Katrina McBethDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Fatima BorichaDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Janice JohnDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Ivan G Magana CeballosDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Giuseppe N ColasurdoDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Maria E TellezDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Tina ReddyDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Wilfredo De Jesús-RojasDepartment of Pediatrics and Basic Sciences, Ponce Health Sciences University, Ponce, PR 00716, USA.ORCID 0000-0002-6133-3517
Ricardo A MosqueraDepartment of Pediatrics, Division of Pulmonary Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn-home palivizumab administration programs (PH) have shown promise in reducing RSV-associated infections. These programs may be particularly beneficial for children with medical complexity (CMC) by limiting their exposure to healthcare-associated infections (HAIs) from non-RSV-related pathogens during transportation and visits to medical facilities.

methodsIn this prospective study, 41 children with CMC less than 2 years of age were randomized by their health insurance to receive PH or in the clinic (PC) during the RSV season (October 2018-April 2019). Patients were stratified by home ventilation. The primary outcome was the total number of face-to-face encounters. Secondary outcomes were unscheduled clinic visits and hospitalizations secondary to the non-RSV LRTIs. Standard frequentist and Bayesian analyses were performed.

resultsAll demographic factors and strata were matched between PH ("

conclusionsThis study suggests that PH administration may reduce healthcare utilization in CMC. Minimizing exposure to healthcare facilities and supporting home-based interventions are promising strategies for this population.

Indexed as

children with medical complexitypalivizumabrespiratory syncytial virus

Identifiers

PMID39457136
PMCPMC11506299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.